Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Inventory (2023 - 2025)

Addex Therapeutics' Inventory history spans 3 years, with the latest figure at $1459.3 billion for Q3 2025.

  • On a quarterly basis, Inventory changed N/A to $1459.3 billion in Q3 2025 year-over-year; TTM through Sep 2025 was $1459.3 billion, a N/A change, with the full-year FY2024 number at $907.3 billion, up 19004624.77% from a year prior.
  • Inventory came in at $1459.3 billion for Q3 2025, up from $907.3 billion in the prior quarter.
  • The five-year high for Inventory was $1459.3 billion in Q3 2025, with the low at $3.8 million in Q1 2024.
  • Historically, Inventory has averaged $591.6 billion across 3 years, with a median of $453.6 billion in 2023.
  • Peak annual rise in Inventory hit 19004624.77% in 2024, while the deepest fall reached 19004624.77% in 2024.
  • Year by year, Inventory stood at $4.8 million in 2023, then surged by 19004624.77% to $907.3 billion in 2024, then skyrocketed by 60.84% to $1459.3 billion in 2025.
  • Business Quant data shows Inventory for ADXN at $1459.3 billion in Q3 2025, $907.3 billion in Q4 2024, and $3.8 million in Q1 2024.